WILLIAMS AND JENSEN, PLLC for PHRMA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
IP Protections related to trade agreements; trade policies impacting pharaceutical development. Legislative proposals related to WTO TRIPS Waiver.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| DANIEL ZIEGLER | Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn |
Medicare/Medicaid MMM
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| DANIEL ZIEGLER | Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| DANIEL ZIEGLER | Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn |
Budget/Appropriations BUD
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| DANIEL ZIEGLER | Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn |
Defense DEF
Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| DANIEL ZIEGLER | Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.